with a nonglucocorticoid immunosuppressive agent such as cyclophosphamide or rituximab (see ungraded position statement below). Ungraded position statement: For patients with active, severe EGPA, either cyclophosphamide or rituximab may be prescribed for remission induction. Cyclophosphamide has been more commonly used for remission induction in patients with active, severe EGPA, given the experience with cyclophosphamide in other forms of vasculitis Recommendation: For patients with active,